We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+0.05%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$3.55B
AUM Growth
+$59.4M
Cap. Flow
+$77M
Cap. Flow %
2.17%
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128

Top Buys

Rank Stock Value
1
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$138M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$131M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$127M
4
MRO
Marathon Oil Corporation
MRO
+$123M
5
CHX
ChampionX
CHX
+$98.3M

Top Sells

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$638M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$51.2M
3
DFS
Discover Financial Services
DFS
+$45.1M
4
SCRM
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$18.4M
5
NSC icon
Norfolk Southern
NSC
+$17.7M

Sector Composition

Rank Sector Weight
1 Energy 26.53%
2 Technology 21.03%
3 Healthcare 14.68%
4 Industrials 8.19%
5 Materials 6.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NFLX icon
376
Netflix
NFLX
$307B
$337K 0.01%
5,000
-35,000
-88% -$2.19M
LYV icon
377
PUT
Live Nation Entertainment
LYV
$42.3B
$336K 0.01%
215,400
-22,500
-9% -$2.13M
CRDF icon
378
Cardiff Oncology
CRDF
$74.7M
$333K 0.01%
+150,000
New +$565K
CRGX
379
DELISTED
CARGO Therapeutics
CRGX
$328K 0.01%
+20,000
New +$380K
EXPE icon
380
Expedia Group
EXPE
$36.8B
$328K 0.01%
2,600
-27,400
-91% -$3.38M
NERV icon
381
Minerva Neurosciences
NERV
$207M
$319K 0.01%
99,856
+212
+0.2% +$574
SRPT icon
382
Sarepta Therapeutics
SRPT
$1.77B
$316K 0.01%
2,000
-4,813
-71% -$618K
CGON icon
383
CG Oncology
CGON
$6.6B
$316K 0.01%
+10,000
New +$347K
VSTM icon
384
Verastem
VSTM
$519M
$299K 0.01%
100,389
+54,157
+117% +$446K
CYPH
385
Cypherpunk Technologies Inc
CYPH
$71.7M
$294K 0.01%
149,772
+42,360
+39% +$111K
SNAP icon
386
Snap
SNAP
$8.83B
$291K 0.01%
+17,500
New +$251K
SCYX icon
387
SCYNEXIS
SCYX
$51.6M
$291K 0.01%
18,160
+444
+3% +$6.86K
TWLO icon
388
Twilio
TWLO
$29.3B
$284K 0.01%
5,000
-27,500
-85% -$1.62M
BGS icon
389
PUT
B&G Foods
BGS
$278M
$282K 0.01%
117,500
– –
CC icon
390
PUT
Chemours
CC
$2.27B
$279K 0.01%
+46,900
New +$1.23M
F icon
391
PUT
Ford
F
$55B
$274K 0.01%
570,900
– –
ALT icon
392
Altimmune
ALT
$585M
$266K 0.01%
40,000
-16,795
-30% -$124K
OTLK icon
393
Outlook Therapeutics
OTLK
$182M
$266K 0.01%
+36,000
New +$289K
AKTS
394
DELISTED
Akoustis Technologies Inc
AKTS
$264K 0.01%
+2,000,000
New +$753K
LVS icon
395
PUT
Las Vegas Sands
LVS
$29.9B
$258K 0.01%
37,200
+15,400
+71% +$719K
NGNE icon
396
Neurogene
NGNE
$710M
$258K 0.01%
+7,100
New +$250K
ZURA icon
397
Zura Bio
ZURA
$542M
$257K 0.01%
+73,396
New +$299K
STWD icon
398
PUT
Starwood Property Trust
STWD
$5.9B
$253K 0.01%
138,100
+72,500
+111% +$1.41M
VERU icon
399
Veru
VERU
$37.1M
$252K 0.01%
29,922
– –
ADPT icon
400
Adaptive Biotechnologies
ADPT
$3.75B
$238K 0.01%
65,745
– –
14 15
16
17 18

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return

UBS O'Connor's Q2 2024 Portfolio in Review

As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.

By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.

  • UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
  • UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
  • UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
  • UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
  • UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
  • UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
  • UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.